Companion Diagnostic Market Research Report- Global Forecast to 2023

Companion Diagnostic Market Research Report- Global Forecast to 2023

ID: MRFR/HC/2231-CRR | November, 2017 | Region: Global | 107 pages | Cooked Research Reports

Companion Diagnostics Market Information: By Technology (PCR, ISH, Immunohistochemistry), Indication (Cancer, Infectious Diseases, Cardiovascular Diseases, CNS Diseases), End User (Pharma & Biotech, Clinical Laboratories, CRO) – Global Forecast to 2023 


Market Synopsis of Companion Diagnostics Market:


Market Scenario:


Companion diagnostics are the tests and tools used to determine the effect of drug molecule on the particular patients and also the potential patients who can be benefited by a specific treatment. The use of companion diagnostic treatments is an exciting field of medical development. The potential value of companion diagnostics for patients is safer treatment with improved outcomes. The focus of medicine has always been on the wellbeing of the individual patient but with medicine becoming an increasing burden on taxpayers, reducing the cost of quality care is now of prime importance. Companion diagnostics offer an innovative way to achieve a better quality of care at a reduced price. Globally the market for companion diagnostics is growing rapidly.


There are various factors which support the growth of the market, these include increasing costs of the drug discovery and development, rising need for the assessment of the efficacy and safety of the drugs, desperate need for the specific medication for rare and chronic disorders, and technological advancements in the companion diagnostics devices. Furthermore, increase in the demand for diagnostic devices for early detection tumors in case of cancer also boost the market growth. 


On the other hand, there are some factors which hinder the growth of the market such as lack of awareness in the developing nations and lack of skilled professionals.


Globally, the market for companion diagnostics is expected to grow at the rate of about 15.4% from 2017 to 2023. 


 


Research Methodology

Companion Diagnostic Market


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation 


Key Players for Companion Diagnostics Market:                                                  


Some of the key players in this market are: Abbott (U.S.), Agilent Technologies (U.S.), ARUP Laboratories (U.S.), F. Hoffmann-La Roche AG. (Germany), Myriad Genetics Inc. (U.S.), QIAGEN N.V. (Germany), and Thermo Fisher Scientific Inc. (U.S.).     

Segmentation    
  
                                                                                                                                
The global companion diagnostics market has been segmented on the basis of technology which comprises of Polymerase chain reaction (PCR), In-situ hybridization, and immunohistochemistry. On the basis of application, market is segmented into cancer, infectious diseases, cardiovascular diseases, CNS diseases, and others. On the basis of end user, market is segmented into pharmaceutical & biotech companies, clinical laboratories, CRO, and other. 


Figure1: Companion Diagnostics Market by Technology, 2016(%)

Global Companion Diagnostics Market

 Regional Analysis:                                                                      


Globally, Americas is the largest market for companion diagnostics. In Americas, North America is the major contributor to the companion diagnostics market owing to an expensive use of advanced diagnostics devices, and alarming need for cancer diagnosis and treatment. According to the American Cancer Society, 1,688,780 new cases are expected to be diagnosed in 2017 in the U.S. It also stated that cancer is the second most common cause of death in the U.S. Furthermore, nearly 41 out 100 men and 38 out of 100 women are expected to develop cancer in their lifetime.


Europe is the second largest market after Americas. Factors attributing to the growth of this market in Europe are rising demand for efficiency in healthcare and strengthening healthcare system. Germany is the largest market in Europe due to the presence of major market players in this regions and growing demand for technological advancement.  Furthermore, the prevalence of cancer is also found to be increasing among European population.


Asia Pacific market is expected to be the fastest growing market for companion diagnostics due to continuous development in countries such as India and China, and increasing healthcare expenditure in these countries. Rising prevalence of lifestyle disease such as diabetes, obesity and cancers also boost the market growth in Asia Pacific.


Middle East & Africa are expected to have a limited but steady growth owing to low healthcare expenditure and demand for primary healthcare services in this region.


Key Finding



  • The companion diagnostics global market and is expected to reach USD 12,647.5 million by 2023

  • PCR based companion diagnostics holds the largest share of 53% of the market

  • America holds the largest market share of companion diagnostics market in 2016 and is anticipated to reach USD 5093.2 million by the end of forecast period

  • Asia Pacific the fastest growing region and expected to grow at the rate of 16% during the forecast period 


Intended Audience



  • Companion Diagnostic Tests Developers & Service Providers

  • Pharmaceutical and Biotechnology Companies

  • Contract Research Organizations (CROs)

  • Research and Development (R&D) Companies

  • Government Research Laboratories

  • Independent Research Laboratories

  • Government and Independent Regulatory Authorities

  • Market Research and Consulting Service Providers

  • Academic Institutes and Universities 


 

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

TABLE OF CONTENTS

2.1 Definition

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

2.5 Market Structure

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4.1 Introduction

4.2 Drivers

4.2.1 High Cost of drug discovery and drug development

4.2.2 Rising need for the assessment of the efficacy and safety of the drugs

4.2.3 Desperate Need of the Specific Medication for the Chronic and Rare Diseases

4.3 Restraints

4.3.1 Inaccuracy of the Tests

4.4 Opportunities

4.4.1 Development of the Companion Diagnostic Tools for Rare Disorders

5.1 Porter’s Five Forces Model

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

6.1 Introduction

6.2 Polymerase Chain Reaction (PCR)

6.3 In-situ Hybridization

6.4 Immunohistochemistry

7.1 Introduction

7.2 Cancer

7.3 Infectious Diseases

7.4 Cardiovascular Diseases

7.5 Central Nervous System Disorders

8.1 Introduction

8.2 Pharma & Biotech Companies

8.3 Clinical Laboratories

8.4 Contract Research Organizations

9.1 Introduction

9.2 America

9.2.1 US

9.2.2 Canada

9.2.3 South America

9.3 Europe

9.3.1 Germany

9.3.2 France

9.3.3 U.K.

9.3.4 Italy

9.3.5 Spain

9.3.6 Rest Of Western Europe

9.3.8 Eastern Europe

9.4 Asia-Pacific

9.4.2 Japan

9.4.3 China

9.4.5 India

9.4.6 Republic of Korea

9.4.8 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

10.1 Introduction

10.2 Company Share Analysis

11.1 Abbott Laboratories

11.1.1 Company Overview

11.1.2 Product/Business Segment Overview 11.1.3 Financial Updates

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Agilent Technologies

11.2.1 Company Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financial Overview

11.2.4 Key Development

11.2.5 SWOT Analysis

11.3 ARUP Laboratories

11.3.1 Company Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 F. Hoffmann-La Roche AG

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Updates

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.5 Myriad Genetics, Inc.

11.5.1 Company Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financial Overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Qiagen N.V.

11.6.1 Company Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financial Overview

11.6.4 Key Development

11.6.5 SWOT Analysis

11.7 Thermo Fisher Scientific Inc.

11.7.1 Company Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

TABLE 1 Global COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD Million)

TABLE 2 Global PCR based Companion Diagnostics MARKET, by region, 2014-2023 (USD Million)

TABLE 3 Global In-situ hybridization based companion diagnostics MARKET, by region, 2014-2023 (USD Million)

TABLE 4 GLOBAL immunohistochemistry BASED COMPANION DIAGNOSTICS MARKET, BY REGION, 2014-2023 (USD MILLION)

TABLE 5 GLOBAL COMPANION DIAGNOSTICS MARKET, BY Application, 2014-2023 (USD MILLION)

TABLE 6 GLOBAL companion diagnostics MARKET for cancer, BY REGION, 2014-2023 (USD MILLION)

TABLE 7 GLOBAl companion diagnostics MARKET for Infectious diseases, BY REGION, 2014-2023 (USD MILLION)

TABLE 8 GLOBAl companion diagnostics MARKET for cardiovascular diseases, BY REGION, 2014-2023 (USD MILLION)

TABLE 9 GLOBAl companion diagnostics MARKET for CNS Disorders, BY REGION, 2014-2023 (USD MILLION)

TABLE 10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY end user, 2014-2023 (USD MILLION)

TABLE 11 GLOBAL Companion Diagnostics MARKET for Pharma & Biotech Companies, BY REGION, 2014-2023 (USD MILLION)

TABLE 12 GLOBAL companion diagnostics MARKET for clinical laboratories, BY REGION, 2014-2023 (USD MILLION)

TABLE 13 GLOBAL companion diagnostics MARKET for CROs, BY REGION, 2014-2023 (USD MILLION)

TABLE 14 GLOBAL COMPANION DIAGNOSTICS MARKET, BY Region, 2014-2023 (USD MILLION)

TABLE 15 america COMPANION DIAGNOSTICS MARKET, BY region, 2014-2023 (USD MILLION)

TABLE 16 AMERICA COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 17 AMERICA COMPANION DIAGNOSTICS MARKET, BY Application, 2014-2023 (USD MILLION)

TABLE 18 AMERICA COMPANION DIAGNOSTICS MARKET, BY End user, 2014-2023 (USD MILLION)

TABLE 19 US COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 20 US COMPANION DIAGNOSTICS MARKET, BY Application, 2014-2023 (USD MILLION)

TABLE 21 US COMPANION DIAGNOSTICS MARKET, BY End user, 2014-2023 (USD MILLION)

TABLE 22 Canada COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 23 Canada COMPANION DIAGNOSTICS MARKET, BY Application, 2014-2023 (USD MILLION)

TABLE 24 Canada COMPANION DIAGNOSTICS MARKET, BY End user, 2014-2023 (USD MILLION)

TABLE 25 South America COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 26 South America COMPANION DIAGNOSTICS MARKET, BY Application, 2014-2023 (USD MILLION)

TABLE 27 South America COMPANION DIAGNOSTICS MARKET, BY End user, 2014-2023 (USD MILLION) TABLE 28 Europe COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2014-2023 (USD MILLION)

TABLE 29 Europe COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 30 Europe COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 31 Europe COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 32 Germany COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 33 Germany COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 34 Germany COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 35 France COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 36 France COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 37 France COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 38 U.K. COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION) TABLE 39 U.K. COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 40 U.K. COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 41 Italy COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 42 Italy COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 43 Italy COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 44 Spain COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 45 Spain COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 46 Spain COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 47 Rest of western Europe COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 48 Rest of western Europe COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 49 Rest of western Europe COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 50 Eastern Europe COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 51 Eastern Europe COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 52 Eastern Europe COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 53 Asia-Pacific COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2014-2023 (USD MILLION)

TABLE 54 Asia-Pacific COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 55 Asia-Pacific COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 56 Asia-Pacific COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 57 Japan COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 58 Japan COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 59 Japan COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 60 China COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 61 China COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 62 China COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 63 India COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 64 India COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 65 India COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 66 Republic of Korea COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 67 Republic of Korea COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 68 Republic of Korea COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 69 Rest of Asia-Pacific COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 70 Rest of Asia-Pacific COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 71 Rest of Asia-Pacific COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 72 Middle East & Africa COMPANION DIAGNOSTICS MARKET, BY Region, 2014-2023 (USD MILLION)

TABLE 73 Middle East & Africa COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 74 Middle East & Africa COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 75 Middle East & Africa COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 76 Middle East COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 77 Middle East COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 78 Middle East COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 79 Africa COMPANION DIAGNOSTICS MARKET, By Technology, 2014-2023 (USD MILLION)

TABLE 80 Africa COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014-2023 (USD MILLION)

TABLE 81 Africa COMPANION DIAGNOSTICS MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 82 Abbott Laboratories: Key Developments

TABLE 83 Agilent technologies: KEY DEVELOPMENT

TABLE 84 F. Hoffmann-La Roche AG: Key development

TABLE 85 Myriad Genetics Inc: Key Developments

TABLE 86 Qiagen: Key Development

TABLE 87 Thermo Fisher Scientific Inc.: Key Developments

FIGURE 1 Global companion diagnostics MARKET SHARE, By Technology, 2016 (%)

FIGURE 2 Global companion diagnostics MARKET SHARE, BY application, 2016 (%)

FIGURE 3 Global companion diagnostics MARKET SHARE, BY end user, 2016 (%)

FIGURE 4 Global companion diagnostics MARKET SHARE, BY region, 2016 (%)

FIGURE 5 Market Structure of GLOBAL companion diagnostics MARKET

FIGURE 6 Research Process of MRFR

FIGURE 7 Drivers, Retraints & Opportunities

FIGURE 8 Porters five forces model

FIGURE 9 Global Companion diagnostics Market, By Technology, 2016 & 2023

FIGURE 10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY Application, 2016 & 2023 (USD MILLION)

FIGURE 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY End user, 2016 & 2023 (USD MILLION)

FIGURE 12 Global COMPANION DIAGNOSTICS MARKET share, By region, 2016 (%)

FIGURE 13 America Companion diagnostics Market Share, By region, 2016 (%)

FIGURE 14 Europe Companion diagnostics Market Share, By Country, 2016 (%)

FIGURE 15 Asia-Pacific Companion diagnostics Market Share, By Country, 2016 (%)

FIGURE 16 Middle East & Africa Companion diagnostics Market, BY Region, 2016 (%)

FIGURE 17 Abbott Laboratories: recent Financials (USD million)

FIGURE 18 Abbott Laboratories: Segmental Revenue, 2016 (%)

FIGURE 19 Abbott Laboratories: Geographical revenue, 2016 (%)

FIGURE 20 Abbott Laboratories: SWOT Analysis

FIGURE 21 Agilent Technologies: RECENT FINANCIALs

FIGURE 22 Agilent: operating segments, 2016 (%)

FIGURE 23 AGILENT Technologies: GEographic Mix, 2016 (%)

FIGURE 24 Agilent technologies: SWOT ANALYSIS

FIGURE 25 F. Hoffmann-La Roche AG: Financial Revenue

FIGURE 26 F. Hoffmann-La Roche AG: Segmental Revenue

FIGURE 27 F. Hoffmann-La Roche AG: geogrpahical Revenue

FIGURE 28 F. HOFFMANN-LA ROCHE AG: SWOT ANALYSIS

FIGURE 29 Myriad Genetics Inc. Recent Financials

FIGURE 30 Myriad Genetics Inc Business Revenue, 2016 (%) FIGURE 31 Myriad Genetics Inc: swot analysis

FIGURE 32 Qiagen N.V.: Recent financials

FIGURE 33 Qiagen N.V.: Segment mix, 2016 (%)

FIGURE 34 Qiagen N.V.: geographic Mix, 2016 (%)

FIGURE 35 QIAGEN N.V.: SWOT ANALYSIS


FIGURE 36 Thermo Fisher Scientific Inc. Recent Financials 104

FIGURE 37 Thermo Fisher Scientific Inc. Business Revenue 104

FIGURE 38 Thermo Fisher Scientific Inc.: geographical Revenue 105

FIGURE 39 Thermo Fisher Scientific: SWOT Analysis 106